Kimmo Taari

University of Helsinki

Finland

Research Interests

Explore related searches

Professors in Finland

Contact this professor

ORCID

Google Scholar

Academic Page

Articles (17)

Expected impact of MRI-targeted biopsy interreader variability among uropathologists on ProScreen prostate cancer screening trial

Article Link

Year:

2024

Prostate Cancer Screening with PSA, Kallikrein Panel, and MRI

Article Link

Year:

2024

Allopurinol and prostate cancer survival in a Finnish population-based cohort

Article Link

Year:

2024

Screening history and risk of death from prostate cancer

Article Link

Year:

2024

Which men benefit from prostate cancer screening? Prostate cancer mortality by subgroup in the European Randomised Study of Screening for Prostate Cancer

Article Link

Year:

2024

Antidiabetic drugs, glycemic control and risk of benign prostatic hyperplasia

Article Link

Year:

2023

Prostate cancer incidence in men with prostate-specific antigen below 3 ng/mL

Article Link

Year:

2023

Statin use and outcomes of oncological treatment for castration-resistant prostate cancer

Article Link

Year:

2023

Testosterone replacement therapy is not associated with increased prostate cancer incidence, prostate cancer-specific, or cardiovascular disease-specific mortality in Finnish men

Article Link

Year:

2023

Population‐based randomized trial of screening for clinically significant prostate cancer ProScreen: a pilot study

Article Link

Year:

2022

Anti-epileptic drugs and prostate cancer-specific mortality compared to non-users of anti-epileptic drugs in the Finnish Randomized Study of Screening for Prostate Cancer

Article Link

Year:

2022

Inverse Association between Statin Use and Cancer Mortality Relates to Cholesterol Level

Article Link

Year:

2022

Outcomes of Screening for Prostate Cancer Among Men Who Use Statins

Article Link

Year:

2022

Estimating the rate of overdiagnosis with prostate cancer screening

Article Link

Year:

2021

Digital rectal examination in prostate cancer screening at PSA level 3.0-3.9 ng/ml

Article Link

Year:

2021

Prostate cancer prognosis after initiation of androgen deprivation therapy among statin users. A population-based cohort study

Article Link

Year:

2021

Antiepileptic drugs and prostate cancer risk in the Finnish Randomized Study of Screening for Prostate Cancer

Article Link

Year:

2021

Collaborators (7)

Teemu J. Murtola

FINLAND

Reija Autio

University of Tampere

FINLAND

Anssi Auvinen

University of Tampere

FINLAND

Tuomas Mirtti

University of Helsinki

FINLAND

Aino Siltari

University of Helsinki

FINLAND

Antti Rannikko

University of Helsinki

FINLAND

Jani Raitanen

University of Tampere

FINLAND

Kimmo Taari

Research Interests

Explore related searches

Contact this professor

Articles (17)

Expected impact of MRI-targeted biopsy interreader variability among uropathologists on ProScreen prostate cancer screening trial

Prostate Cancer Screening with PSA, Kallikrein Panel, and MRI

Allopurinol and prostate cancer survival in a Finnish population-based cohort

Screening history and risk of death from prostate cancer

Which men benefit from prostate cancer screening? Prostate cancer mortality by subgroup in the European Randomised Study of Screening for Prostate Cancer

Antidiabetic drugs, glycemic control and risk of benign prostatic hyperplasia

Prostate cancer incidence in men with prostate-specific antigen below 3 ng/mL

Statin use and outcomes of oncological treatment for castration-resistant prostate cancer

Testosterone replacement therapy is not associated with increased prostate cancer incidence, prostate cancer-specific, or cardiovascular disease-specific mortality in Finnish men

Population‐based randomized trial of screening for clinically significant prostate cancer ProScreen: a pilot study

Anti-epileptic drugs and prostate cancer-specific mortality compared to non-users of anti-epileptic drugs in the Finnish Randomized Study of Screening for Prostate Cancer

Inverse Association between Statin Use and Cancer Mortality Relates to Cholesterol Level

Outcomes of Screening for Prostate Cancer Among Men Who Use Statins

Estimating the rate of overdiagnosis with prostate cancer screening

Digital rectal examination in prostate cancer screening at PSA level 3.0-3.9 ng/ml

Prostate cancer prognosis after initiation of androgen deprivation therapy among statin users. A population-based cohort study

Antiepileptic drugs and prostate cancer risk in the Finnish Randomized Study of Screening for Prostate Cancer

Collaborators (7)

Teemu J. Murtola

Reija Autio

Anssi Auvinen

Tuomas Mirtti

Aino Siltari

Antti Rannikko

Jani Raitanen

How do I reach out?

Meet Kite AI